25,736 Shares in Enfusion, Inc. (NYSE:ENFN) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new position in Enfusion, Inc. (NYSE:ENFN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,736 shares of the company's stock, valued at approximately $265,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its position in shares of Enfusion by 9.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 365,512 shares of the company's stock worth $3,469,000 after buying an additional 31,743 shares during the period. Martingale Asset Management L P boosted its stake in Enfusion by 26.2% during the third quarter. Martingale Asset Management L P now owns 74,360 shares of the company's stock worth $706,000 after acquiring an additional 15,424 shares in the last quarter. PDT Partners LLC acquired a new stake in Enfusion in the third quarter worth $867,000. Paloma Partners Management Co bought a new stake in Enfusion in the third quarter valued at $157,000. Finally, Azora Capital LP raised its holdings in shares of Enfusion by 6.8% during the third quarter. Azora Capital LP now owns 29,827 shares of the company's stock valued at $283,000 after purchasing an additional 1,890 shares during the period. 81.05% of the stock is currently owned by institutional investors.

Enfusion Price Performance

Shares of NYSE:ENFN traded down $0.04 during midday trading on Tuesday, hitting $11.12. 703,135 shares of the company's stock were exchanged, compared to its average volume of 555,782. Enfusion, Inc. has a 12 month low of $7.83 and a 12 month high of $11.80. The company has a market cap of $1.43 billion, a PE ratio of 277.94, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The stock has a 50 day moving average price of $11.18 and a 200-day moving average price of $10.26.

Remove Ads

Enfusion (NYSE:ENFN - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). The company had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. On average, analysts anticipate that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Insider Buying and Selling

In other Enfusion news, CFO Bradley Herring sold 4,134 shares of the company's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $41,877.42. Following the completion of the sale, the chief financial officer now directly owns 266,369 shares of the company's stock, valued at approximately $2,698,317.97. This represents a 1.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Oleg Movchan sold 2,771 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the sale, the chief executive officer now owns 526,702 shares of the company's stock, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,346 shares of company stock worth $868,109. 36.44% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ENFN has been the subject of several research reports. William Blair restated a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th. Stifel Nicolaus raised their price objective on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. Finally, Piper Sandler upped their target price on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.